Previous 10 | Next 10 |
The Board learned of the arrest of Dr. Serhat Gumrukçu after the Press Release by the Department of Justice on May 25, 2022; The Board has verified that the incident leading to the arrest occurred prior to the merger which created the Enochian of today, and is completel...
Enochain Biosciences (ENOB) plummeted 36% after Hindenburg Research said it was short the firm. Hindenburg Research tweeted that it plans to release a report on the company's co-founder Serhat Gumrukcu next week. ENOB short interest is 17%. For further details see: Enoch...
LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, today is announcing the appointment of Dr. François Binette, Ph.D. as Execu...
LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ: ENOB), a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, announced today that Greg Duczynski is joining as Senior Vice President for Clinical Operations afte...
Innovative Clinical Strategies to Treat HIV and Cancer Presented by Pioneering Research Scientist at the Innate Killer Summit in San Diego PR Newswire LOS ANGELES , April 6, 2022 /PRNewswire/ -- Dr. Serhat Gumrukçu, inventor and co-founder of En...
LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced that Dr. Serhat Gumrukçu, the inventor and co-founder of the Company, deliver...
LOS ANGELES, March 15, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, has issued an exclusive sub-license of one of its proprietary technologies that could improve...
LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, Inventor and Co-Founder of Enochian BioScienc...
Shares of Enochian Biosciences Inc. (NASDAQ:ENOB) traded today at $13.76, eclipsing its 52-week high. So far today approximately 15.1 million shares have been exchanged, as compared to an average 30-day volume of 182,000 shares. Enochian BioSciences Inc is a biopharmaceutical company. It...
LOS ANGELES, Oct. 18, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an Investigator Pre-Investigational New Drug (IND) pro...
News, Short Squeeze, Breakout and More Instantly...
Enochian Biosciences Inc. Company Name:
ENOB Stock Symbol:
NASDAQ Market:
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise that its 2023 Annual Stockholder Meeting (the “Annual Meeting”), which was sched...